Impact of baseline blood pressure on all-cause mortality in patients with atrial fibrillation: results from a multicenter registry study

Abstract Background: The ideal blood pressure (BP) target for patients with atrial fibrillation (AF) is still unclear. The present study aimed to assess the effect of the baseline BP on all-cause mortality in patients with AF. Methods: This registry study included 20 emergency centers across China and consecutively enrolled patients with AF from 2008 to 2011. All participants were followed for 1 year ± 1 month. The primary endpoint was all-cause mortality. Results: During the follow-up, 276 (13.9%) all-cause deaths occurred. Kaplan–Meier curves showed that a systolic blood pressure (SBP) ≤110 mmHg or >160 mmHg was associated with a higher risk of all-cause mortality (log-rank test, P = 0.014), and a diastolic blood pressure (DBP) <70 mmHg was associated with the highest risk of all-cause mortality (log-rank test, P = 0.002). After adjusting for confounders, the multivariable Cox regression model suggested that the risk of all-cause mortality was increased in the group with SBP ≤110 mmHg (hazard ratio [HR], 1.963; 95% confidence interval [CI], 1.306–2.951), and DBP <70 mmHg (HR, 1.628; 95% CI, 1.163–2.281). In the restricted cubic splines, relations between baseline SBP or DBP and all-cause mortality showed J-shaped associations (non-linear P <0.001 and P = 0.010, respectively). The risk of all-cause mortality notably increased at a lower baseline SBP and DBP. Conclusions: Having a baseline SBP ≤110 mmHg or DBP <70 mmHg was associated with a significantly higher risk of all-cause mortality in patients with AF. An excessively low BP may not be an optimal target for patients with AF.

[1]  Li Zhong,et al.  Role of circulating long non-coding RNA for the improvement of the predictive ability of the CHA2DS2–VASc score in patients with atrial fibrillation , 2022, Chinese medical journal.

[2]  J. Manson,et al.  Low Diastolic Blood Pressure and Mortality in Older Women. Results from the Women's Health Initiative Long Life Study. , 2022, American journal of hypertension.

[3]  Jun Zhu,et al.  Impact of renin–angiotensin–aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension , 2022, BMC Cardiovascular Disorders.

[4]  Y. Gunes,et al.  Poorly controlled hypertension is associated with elevated serum uric acid to HDL-cholesterol ratio: a cross-sectional cohort study , 2022, Postgraduate medicine.

[5]  Jun Zhu,et al.  Impact of renin–angiotensin–aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension , 2021, BMC Cardiovascular Disorders.

[6]  Xin Zheng,et al.  Discharge heart rate and 1-year clinical outcomes in heart failure patients with atrial fibrillation , 2021, Chinese medical journal.

[7]  G. Lip,et al.  Average Systolic Blood Pressure and Clinical Outcomes in Patients with Atrial Fibrillation: Prospective Data from COOL-AF Registry , 2021, Clinical interventions in aging.

[8]  Weili Zhang,et al.  Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. , 2021, The New England journal of medicine.

[9]  R. Bai,et al.  A simple and easily implemented risk model to predict 1-year ischemic stroke and systemic embolism in Chinese patients with atrial fibrillation , 2021, Chinese medical journal.

[10]  S. Raposeiras-Roubín,et al.  Renin-Angiotensin System Inhibitors Prognostic Benefit in Older Patients With Atrial Fibrillation. , 2021, Journal of the American Medical Directors Association.

[11]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[12]  S. Yusuf,et al.  Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. , 2020, European heart journal.

[13]  M. Chung,et al.  Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. , 2020, Circulation.

[14]  A. Dominiczak,et al.  Diastolic Blood Pressure J-Curve Phenomenon in a Tertiary-Care Hypertension Clinic , 2019, Hypertension.

[15]  M. Ezekowitz,et al.  Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry). , 2019, The American journal of cardiology.

[16]  G. Lip,et al.  Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population , 2019, European heart journal.

[17]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)]. , 2018, Giornale italiano di cardiologia.

[18]  G. Lip,et al.  Ideal Blood Pressure in Patients With Atrial Fibrillation. , 2018, Journal of the American College of Cardiology.

[19]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[20]  U. Heemann,et al.  Association of Ambulatory Blood Pressure with All-Cause and Cardiovascular Mortality in Hemodialysis Patients: Effects of Heart Failure and Atrial Fibrillation. , 2018, Journal of the American Society of Nephrology : JASN.

[21]  Wilbert S Aronow,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Hypertension.

[22]  R. Brook,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.

[23]  G. Reboldi,et al.  Hypertension and Atrial Fibrillation: Doubts and Certainties From Basic and Clinical Studies , 2018, Circulation research.

[24]  M. Cho,et al.  Reverse J-Curve Relationship Between On-Treatment Blood Pressure and Mortality in Patients With Heart Failure. , 2017, JACC. Heart failure.

[25]  A. Manolis,et al.  Atrial fibrillation and arterial hypertension , 2017, Pharmacological research.

[26]  J. Laukkanen,et al.  Association of left atrial enlargement with ventricular remodeling in hypertensive Chinese elderly , 2017, Echocardiography.

[27]  Hynek Pikhart,et al.  Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants , 2017, The Lancet.

[28]  Sally Hopewell,et al.  Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis , 2016, British Medical Journal.

[29]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[30]  Youping Xiong,et al.  The Burden of Hypertension and Associated Risk for Cardiovascular Mortality in China. , 2016, JAMA internal medicine.

[31]  Sudha Seshadri,et al.  50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study , 2015, The Lancet.

[32]  M. Volpe,et al.  Blood Pressure Control versus Atrial Fibrillation Management in Stroke Prevention , 2015, Current Hypertension Reports.

[33]  D. Wyse,et al.  Systolic blood pressure and mortality in patients with atrial fibrillation and heart failure: insights from the AFFIRM and AF‐CHF studies , 2014, European journal of heart failure.

[34]  George R. Marzouka,et al.  Optimal blood pressure in patients with atrial fibrillation (from the AFFIRM Trial). , 2014, The American journal of cardiology.

[35]  S. Nattel,et al.  Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. , 2014, Journal of the American College of Cardiology.

[36]  R. Puri,et al.  Clinic , 1907, The American journal of dental science.

[37]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.

[38]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[39]  S. Sarıkaya,et al.  NEUTROPHIL TO LYMPHOCYTE RATIO IS A USEFUL PREDICTOR OF ATRIAL FIBRILLATION IN PATIENTS WITH DIABETES MELLITUS , 2013 .

[40]  M. J. Charron,et al.  Downregulation of uncoupling protein 2 mRNA in white adipose tissue and uncoupling protein 3 mRNA in skeletal muscle during the early stages of leptin treatment. , 1999, Diabetes.